The need to find minimally invasive, feasible biomarkers that reliably aid physicians in ideal patient selection is ongoing with many already identified, being PD-L1 tumor scoring and the tumor mutational burden (TMB) the most established in clinical use, with some limitations [4]. This evidence concerns the gene CD274 and neoplasm.